Literature DB >> 22187315

Urinary heparanase activity in patients with Type 1 and Type 2 diabetes.

Angelique L W M M Rops1, Mabel J van den Hoven, Bart A Veldman, Simone Salemink, Gerald Vervoort, Lammy D Elving, Jan Aten, Jack F Wetzels, Johan van der Vlag, Jo H M Berden.   

Abstract

BACKGROUND: A reduced heparan sulphate (HS) expression in the glomerular basement membrane of patients with overt diabetic nephropathy is associated with an increased glomerular heparanase expression. We investigated the possible association of urinary heparanase activity with the development of proteinuria in patients with Type 1 diabetes (T1D), Type 2 diabetes (T2D), or membranous glomerulopathy (MGP) as non-diabetic disease controls.
METHODS: Heparanase activity, albumin, HS and creatinine were measured in the urine of patients with T1D (n=58) or T2D (n=31), in patients with MGP (n=52) and in healthy controls (n=10). Heparanase messenger RNA (mRNA) expression in leukocytes was determined in a subgroup of patients with T1D (n=19).
RESULTS: Urinary heparanase activity was increased in patients with T1D and T2D, which was more prominent in patients with macroalbuminuria, whereas no activity could be detected in healthy controls. Albuminuria levels were associated with increased urinary heparanase activity in diabetic patients (r=0.20; P<0.05) but not in patients with MGP (r=0.11; P=0.43). A lower urinary heparanase activity was observed in diabetic patients treated with inhibitors of the renin-angiotensin-aldosterone system (RAAS), when compared to diabetic patients treated with other anti-hypertensives. Additionally, urinary heparanase activity was associated with age in T1D and MGP. In MGP, heparanase activity and β2-microglobulin excretion correlated. In patients with T1D, no differences in heparanase mRNA expression in leukocytes could be observed.
CONCLUSIONS: Urinary heparanase activity is increased in diabetic patients with proteinuria. However, whether increased heparanase activity is a cause or consequence of proteinuria requires additional research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22187315     DOI: 10.1093/ndt/gfr732

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

Review 1.  The Role of Heparan Sulfate in Inflammation, and the Development of Biomimetics as Anti-Inflammatory Strategies.

Authors:  Brooke L Farrugia; Megan S Lord; James Melrose; John M Whitelock
Journal:  J Histochem Cytochem       Date:  2018-01-01       Impact factor: 2.479

Review 2.  Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression.

Authors:  Sunil Rangarajan; Jillian R Richter; Robert P Richter; Shyam K Bandari; Kaushlendra Tripathi; Israel Vlodavsky; Ralph D Sanderson
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 3.  Impact of heparanase on renal fibrosis.

Authors:  Valentina Masola; Gianluigi Zaza; Maurizio Onisto; Antonio Lupo; Giovanni Gambaro
Journal:  J Transl Med       Date:  2015-06-04       Impact factor: 5.531

4.  Heparanase mediates renal dysfunction during early sepsis in mice.

Authors:  Melissa I Lygizos; Yimu Yang; Christopher J Altmann; Kayo Okamura; Ana Andres Hernando; Mario J Perez; Lynelle P Smith; Daniel E Koyanagi; Aneta Gandjeva; Rhea Bhargava; Rubin M Tuder; Sarah Faubel; Eric P Schmidt
Journal:  Physiol Rep       Date:  2013-11-11

5.  Nephroprotective effect of heparanase in experimental nephrotic syndrome.

Authors:  Suheir Assady; Joel Alter; Elena Axelman; Yaniv Zohar; Edmond Sabo; Michael Litvak; Marielle Kaplan; Neta Ilan; Israel Vlodavsky; Zaid Abassi
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

6.  Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase.

Authors:  Valentina Masola; Gianluigi Zaza; Simona Granata; Giovanni Gambaro; Maurizio Onisto; Antonio Lupo
Journal:  J Transl Med       Date:  2013-11-20       Impact factor: 5.531

7.  A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition.

Authors:  Valentina Masola; Maurizio Onisto; Gianluigi Zaza; Antonio Lupo; Giovanni Gambaro
Journal:  J Transl Med       Date:  2012-10-24       Impact factor: 5.531

Review 8.  Heparanase and autoimmune diabetes.

Authors:  Charmaine J Simeonovic; Andrew F Ziolkowski; Zuopeng Wu; Fui Jiun Choong; Craig Freeman; Christopher R Parish
Journal:  Front Immunol       Date:  2013-12-26       Impact factor: 7.561

9.  The protective role of fucosylated chondroitin sulfate, a distinct glycosaminoglycan, in a murine model of streptozotocin-induced diabetic nephropathy.

Authors:  Conrado L R Gomes; Cristina L Leão; Carolina Venturotti; André L Barreira; Gabriela Guimarães; Roberto J C Fonseca; Rodrigo S Fortunato; Paulo A S Mourão; Alvimar G Delgado; Christina M Takiya; Maurilo Leite
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

Review 10.  Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy.

Authors:  Dorin-Bogdan Borza
Journal:  Front Immunol       Date:  2016-04-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.